Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2

Shiqi Wang, Saowanee Wannasarit, Patricia Figueiredo, Giuseppina Molinaro, Yaping Ding, Alexandra Correia, Luca Casettari, Ruedeekorn Wiwattanapatapee, Jouni Hirvonen, Dongfei Liu, Wei Li, Hélder A. Santos

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Sammanfattning

In this study, a rationally designed nanocomposite (BUDPDA@MAP) composed of polydopamine (PDA) nanoparticle and anti‐inflammatory drug budesonide (BUD) encapsulated in a pH‐responsive endosomolytic polymer (poly(butyl methacrylate‐co‐methacrylic acid) grafted acetalated dextran, denoted by MAP), is proposed. The uniform nanocomposite is prepared using a microfluidic device. At low endosomal pH (5.5), MAP destabilizes the endosomal membranes for the cytoplasmic delivery of PDA, and releases BUD simultaneously, resulting in a greater reactive oxygen species scavenging capability than both the free drug and PDA alone. The combined therapeutic efficacy from PDA and BUD also leads to a successful macrophage phenotype switch from pro‐inflammatory M1 to anti‐inflammatory M2.
Originalspråkengelska
Artikelnummer2000058
TidskriftAdvanced Therapeutics
Volym4
Utgåva1
Antal sidor11
ISSN2366-3987
DOI
StatusPublicerad - jan. 2021
MoE-publikationstypA1 Tidskriftsartikel-refererad

Vetenskapsgrenar

  • 317 Farmaci
  • 221 Nanoteknologi
  • 318 Medicinsk bioteknologi

Citera det här